James Moe MBA, PhD

Dr. Moe served as the Director of Product Development, PI, R&D at Q-RNA, Inc. During his tenure at Q-RNA, he led the drug discovery and optimization efforts to design compounds aimed at providing effective drugs to treat Alzheimer's disease. His research was focused on understanding the molecular basis of protein-protein interactions applicable to neurodegenerative diseases to develop biomarker approaches targeting tau oligomers. It was at Q-RNA where Dr. Moe and Dr. Davidowitz first conceived of Oligomerix.
Before joining Q RNA, he spent more than 20 years in academic and industrial research in drug discovery, diagnostics and medical devices, including positions he held at Gene-Trak, Vysis, bioMerieux, Mosaic Technologies and Spire Corporation.

Dr. Moe earned his Ph.D. in Molecular Biology and Biochemistry/Biophysics from Wesleyan University, his Postdoctoral in Molecular Toxicology from Vanderbilt University and his MBA, with a concentration in entrepreneurial studies, from Boston University.